Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/23/2025

Treatment of Neonatal Jaundice from Rh Hemolytic Disease

Introduction to Phototherapy

  • The American Academy of Pediatrics recommends intensive phototherapy as the primary treatment for neonatal jaundice due to Rh incompatibility, using blue LED lights (460-490 nm) at irradiance ≥30 μW·cm⁻²·nm⁻¹, with intravenous immunoglobulin (IVIG) 0.5 g/kg administered if bilirubin rises rapidly despite phototherapy, to prevent exchange transfusion and kernicterus 1

Immediate Phototherapy Initiation

  • Intensive phototherapy should be started immediately when total serum bilirubin (TSB) exceeds age-specific thresholds for hemolytic disease, as Rh incompatibility creates a high-risk hemolytic profile requiring lower treatment thresholds than non-hemolytic jaundice 1, 2

Optimal Phototherapy Parameters

  • Blue LED light sources with peak wavelength 460-490 nm (optimal at 478 nm) should be used, delivering irradiance ≥30 μW·cm⁻²·nm⁻¹ 3, 4
  • Lights should be positioned 10-15 cm above the infant to maximize irradiance delivery 1
  • Skin exposure should be maximized by removing all clothing except diaper and applying eye protection 1, 5
  • The maximum body surface area should be illuminated using overhead devices with large footprints or circumferential (360°) systems 4, 6
  • Irradiance levels should be verified with a calibrated spectral radiometer before and during treatment 3, 6

IVIG as Adjunctive Therapy

  • IVIG 0.5 g/kg should be administered intravenously over 2-4 hours when bilirubin rises ≥0.5 mg/dL per hour despite phototherapy, as it significantly reduces exchange transfusion rates in Rh hemolytic disease 1

Monitoring Requirements

  • Total serum bilirubin (TSB) should be measured within 4-24 hours after initiating phototherapy, depending on initial level and rate of rise 1
  • Values should be plotted on hour-specific nomograms designed for hemolytic disease 1
  • Patients should be monitored for signs of acute bilirubin encephalopathy, such as poor feeding, lethargy, high-pitched cry, and abnormal tone 5
  • Hydration status should be assessed, and IV fluids should be provided if dehydration is present or oral intake is inadequate 1

Critical Safety Measures

  • Phototherapy should not be interrupted until a documented bilirubin decrease occurs, then brief interruptions for feeding and bonding are acceptable 5, 7
  • Eye masks should be used to prevent theoretical retinal damage, although human data are lacking 7
  • Phototherapy does not exacerbate hemolysis 7
  • Contraindications for phototherapy include congenital porphyria and photosensitizing drug exposure 5, 7